StockData

Liminatus Pharma, Inc. (LIMN) stock

LIMNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMNW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30
$2.68−0.13 (-4.63%)

Close on Nov 18, 2026Market cap $179.99MP/E –Yield –

Liminatus Pharma revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

No revenue figures for Liminatus Pharma

Liminatus Pharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Liminatus Pharma figures

See a number that looks wrong?